GlassScriptPhysician profile
Anne L Milam
NPI 1972639573
$6,990.60
in general payments reported to CMS, 2019-2025
33 companies · $3,084 in 2025
The $3,084 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $850 · 2022: $678 · 2023: $730 · 2024: $1,649 · 2025: $3,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,231.90 | 2022-2025 | Descovy, Livdelzi, Yeztugo |
| Genzyme Corporation | $684.41 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $679.53 | 2021-2025 | Airsupra, Flumist Quadrivalent |
| Amgen INC. | $402.10 | 2024-2025 | Krystexxa, Repatha, Repatha |
| Abbott Laboratories | $389.70 | 2023-2025 | Proclaim, Eterna, Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $339.86 | 2021-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $274.28 | 2022-2025 | |
| Glaxosmithkline, LLC. | $229.01 | 2021 | |
| Genentech USA, INC. | $197.36 | 2021 | |
| Averitas Pharma INC. | $149.98 | 2025 | Qutenza |
| Abbvie INC. | $143.82 | 2025 | |
| Phathom Pharmaceuticals, INC. | $127.21 | 2025 | Voquezna |
| Shionogi INC | $124.22 | 2025 | |
| Boston Scientific Corporation | $124.17 | 2025 | Watchman Flx |
| Stemline Therapeutics INC. | $121.84 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $119.79 | 2022 | |
| Horizon Therapeutics Plc | $119.11 | 2023 | Krystexxa |
| Tris Pharma INC | $118.70 | 2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Viiv Healthcare Company | $112.88 | 2025 | Apretude |
| Sandoz INC. | $112.43 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.96 | 2025 | |
| Alk-Abello, INC | $104.54 | 2023 | Grastek, Odactra, Ragwitek |
| Lilly USA, LLC | $103.95 | 2025 | Kisunla |
| Corcept Therapeutics | $98.75 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $97.47 | 2025 | |
| Astellas Pharma US INC | $96.96 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $96.07 | 2022 | |
| Bridgebio Pharma, INC. | $94.39 | 2025 | Attruby |
| Teleflex LLC | $88.62 | 2025 | Barrigel |
| Biosense Webster, INC. | $79.50 | 2024 | Carto 3 |
| Genentech, INC. | $79.12 | 2021 | |
| Abiomed | $75.41 | 2024 | Impella |
| Phadia US INC. | $67.56 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Milam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.